Memantine + Sertraline Effective for Major Depressive Disorder

Share this content:
Memantine + Sertraline Effective for Major Depressive Disorder
Memantine + Sertraline Effective for Major Depressive Disorder

MONDAY, Nov. 7, 2016 (HealthDay News) -- The combination of memantine plus sertraline is efficacious for major depressive disorder, according to a study published online Nov. 3 in the Journal of Clinical Pharmacy and Therapeutics.

Meysam Amidfar, Ph.D., from the Tehran University of Medical Sciences in Iran, and colleagues recruited 66 outpatients with a diagnosis of moderate-to-severe major depressive disorder to participate in a randomized trial. Sixty-two participants completed six weeks of treatment with memantine plus sertraline or placebo plus sertraline. The Hamilton Depression Rating Scale (HDRS) was used to evaluate patients at baseline and at weeks two, four, and six.

The researchers observed a significant time × treatment interaction on the HDRS score in repeated-measures analysis (P = 0.007). The memantine group had significantly greater improvement at all three follow-up sessions, and significantly greater response rates at weeks four and six. The memantine group also had significantly more early improvers and more rapid response to treatment. Both groups had a significant reduction in the HDRS score from baseline to the study end point (both P < 0.001). There were no serious adverse events reported.

"A six-week course of treatment with memantine as adjunct to sertraline showed a favorable safety and efficacy profile in patients with major depressive disorder," the authors write. "Nonetheless, larger controlled studies of longer duration are necessary to assess long-term safety, efficacy, and optimal dosing."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gene Tx Approved for Certain Types of B-Cell Lymphoma

Gene Tx Approved for Certain Types of B-Cell ...

First such treatment for certain types of non-Hodgkin lymphoma

Uninsurance Down by One-Third for Cancer Diagnoses in 2014

Uninsurance Down by One-Third for Cancer Diagnoses in ...

Significant decreases in uninsurance seen across all stages and sites assessed in first year of ACA

Diabetes Ups Risk of MACE in Acute Coronary Syndromes

Diabetes Ups Risk of MACE in Acute Coronary ...

Diabetes, but not pre-diabetes, tied to increased risk of major adverse cardiac events in adjusted model

is free, fast, and customized just for you!

Already a member?

Sign In Now »